-
Mashup Score: 14Illustrated Glossary - NEJM - 2 year(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 4Illustrated Glossary - NEJM - 2 year(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Illustrated Glossary - NEJM - 2 year(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 6Illustrated Glossary - NEJM - 2 year(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 2Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma - 2 year(s) ago
In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy…
Source: New England Journal of MedicineCategories: Hem/Onc News and Journals, Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 14Illustrated Glossary - NEJM - 2 year(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 12Illustrated Glossary - NEJM - 2 year(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 10Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma - 2 year(s) ago
In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, as second-line treatment had significantly longer event-free survival than those who received standard care.
Source: New England Journal of MedicineCategories: Expert Picks, Latest HeadlinesTweet-
Conclusion: axi-cel should be standard second-line treatment for patients with DLBCL who relapse within the first year. Hopefully this OS benefit leads to regulatory approval in 2L context in many places Full paper out at @NEJM : https://nejm.org/doi/full/10.1056/NEJMoa2301665?query=featured_home #ASCO23 #lymsm
-
-
Mashup Score: 29Illustrated Glossary - NEJM - 2 year(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 9Illustrated Glossary - NEJM - 2 year(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
G protein–coupled receptor: A cell‐surface receptor that, once activated by ligand at the cell’s exterior, sets off a cascade of intracellular events. https://t.co/nsFrw4H9aT Explore more terms from the NEJM Illustrated Glossary: https://t.co/6Ixo6ozq1Z